Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines emerging and past therapies for recurrent implantation failure, focusing on three innovative strategies: PBMC, G-CSF, and PRP, but reports no new clinical results.

This study found that treatment with ritlecitinib improved hair regrowth in alopecia areata patients, with many achieving significant results after 24 weeks compared to placebo.

This study found that tofacitinib may be effective in treating various pediatric rheumatic diseases, particularly juvenile idiopathic arthritis, although some patients did not respond, and side effects were observed.

Infliximab was effective in treating a scalp condition that did not respond to other treatments.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

This study found that ALRN-6924 effectively protected human hair follicles from cyclophosphamide-induced damage in an ex vivo setting, suggesting it may reduce both acute and permanent chemotherapy-induced alopecia.

This review discusses the discovery and potential therapeutic uses of proteasome inhibitors across various diseases, including cancer and autoimmune conditions, but does not present new clinical data.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.

This study analyzed pexidartinib-associated adverse events from FDA data and reported common events such as hepatic issues and systemic reactions. It highlighted sex-specific susceptibilities and reinforced the need for risk mitigation and long-term monitoring in tenosynovial giant cell tumor management.

This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

This case report details a probable severe adverse event associated with ritlecitinib for alopecia areata, highlighting risks of pulmonary emboli, infection, atrial fibrillation, and acute kidney injury despite an absence of known risk factors.

This study found that RXR-alpha is strongly expressed in both normal and psoriatic human skin, suggesting it may play a role in the transition from proliferation to differentiation in epidermal keratinocytes.

This review reports that ritlecitinib, baricitinib, and deuruxolitinib, all JAK inhibitors, are effective treatments for moderate-to-severe alopecia areata, with differences in selectivity and onset of action, and suggests that emerging biologic therapies may enhance treatment by offering more targeted immune modulation.

This report describes a case where rituximab provided durable remission in a patient with refractory aggressive diffuse B-cell lymphoma that was unresponsive to prior chemotherapy.

This article discusses the use of Platelet Rich Plasma therapy for skin rejuvenation and hair loss and reports no new clinical results, noting its minimally invasive nature and effect on skin texture and elasticity.

CRISPR/Cas9 and prime editing can potentially fix skin disorder genes safely and effectively.

In this case report, a patient with severe erythrodermic psoriasis and diffuse alopecia who was unresponsive to conventional treatments showed complete resolution of skin lesions and alopecia after being treated with ixekizumab.

This case report describes a patient with lichen planopilaris who experienced remarkable hair regrowth at a previously scarred area after treatment with low-dose naltrexone and platelet-rich plasma, following minimal response to other therapies.

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

This pilot study suggests that a new preparation of platelet-rich plasma gel may improve symptoms and tissue regeneration in patients with en coup de sabre scleroderma, though further trials are needed to clarify its role.

This case study described a 17-year-old with paradoxical psoriasis and ulcerative colitis, triggered by TNF-α inhibitor therapy, who experienced clinical improvement and hair regrowth after switching to ustekinumab, which the authors note aligns with existing data on its effectiveness for these conditions.

In a mouse study, JAK inhibitors like Jakafi and Xeljanz prevented alopecia areata and aided hair regrowth; similar effects were observed in three patients with the condition.

This study found that oral paclitaxel combined with encequidar improved tumor response rates compared to intravenous paclitaxel in women with metastatic breast cancer, while also reducing neuropathy but increasing certain gastrointestinal and neutropenic side effects.

This report documents the successful use of theophylline in treating an 11-year-old girl with a rare immunodeficiency syndrome, suggesting potential in drug repurposing for primary immunodeficiency disorders and asthma.

In this survey of dermatologists, pimozide was most commonly identified as the preferred first-line antipsychotic for treating delusions of parasitosis, followed by risperidone.

In this open-label trial, tofacitinib showed dramatic clinical responses in most patients with moderate-to-severe alopecia areata, supporting further research into JAK inhibitors for this condition.

This study reported that high-dose mizoribin therapy may be effective and safe for managing steroid-dependent pediatric systemic lupus erythematosus but requires monitoring of serum uric acid levels due to potential side effects.

This review discusses the applications of autologous platelet concentrates in aesthetic medicine, highlighting that platelet-rich fibrin is favored over platelet-rich plasma due to cost-effectiveness and efficacy, but reports no new clinical results.